Emad Shash: Our latest review on ‘Prevention of Paclitaxel-Induced Peripheral Neuropathy’
Emad Shash, General Manager of the Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University, shared on LinkedIn:
“New Review Alert!
We are excited to share our latest review article on ‘Prevention of Paclitaxel-Induced Peripheral Neuropathy: A Literature Review of Potential Pharmacological Interventions,’ published in the Future Journal of Pharmaceutical Sciences.
Key Highlights:
Paclitaxel is a cornerstone chemotherapy for many cancers but often causes debilitating peripheral neuropathy.
Our review covers promising preclinical and clinical studies exploring various pharmacological agents for PIPN prevention.
Antioxidants, anti-inflammatory agents, nutritional supplements, and more are showing potential in reducing PIPN incidence and severity.
Why It Matters:
Up to 97% of patients on paclitaxel experience peripheral neuropathy, impacting their quality of life and treatment outcomes. Identifying effective preventive measures is crucial for improving patient care.
Special Thanks:
A huge thank you to all my co-authors for their invaluable contributions to this work. A special acknowledgment to Dr. Aalaa Mahmoud El-Rifai. for her exceptional efforts and dedication throughout this research.”
Source: Emad Shash/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023